Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment

Marzia Pesaresi, Carlo Lovati, Pierluigi Bertora, Enrico Mailland, Daniela Galimberti, Elio Scarpini, Pierluigi Quadri, Gianluigi Forloni, Claudio Mariani

Research output: Contribution to journalArticlepeer-review


We compared plasma levels of beta-amyloid 1-42 (pg/ml) found for 146 sporadic Alzheimer (AD) patients, 89 subjects with mild cognitive impairment (MCI) and 89 age-matched controls (CT). AD patients had significantly lower levels (38, 54, 52; p <0.01), unrelated to severity of the disease as assessed by MMSE score, age, sex or APOE4 status. Twenty cases investigated at two time points 18 months apart did not demonstrate further decreases. Thus, the reduction in beta-amyloid 1-42 may be a marker for AD status, specifically, a transition from normal status or MCI to AD, rather than a marker for neurodegenerative processes occurring in the disease.

Original languageEnglish
Pages (from-to)904-905
Number of pages2
JournalNeurobiology of Aging
Issue number6
Publication statusPublished - Jun 2006


  • Aging
  • Apoe
  • Biological markers
  • Gender
  • Protein precursor of amyloid

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)


Dive into the research topics of 'Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment'. Together they form a unique fingerprint.

Cite this